Clinical Trials Browser

Phase 1/2 × Completed × NPI 2358 × Clear all

NCT03575793 2026-01-20

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Phase 1/2 Completed

39 enrolled 18 charts

Lung Neoplasms

NCT00630110 2011-08-16

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

Neoplasms